A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone

Pharmacotherapy

Volumn 25, Issue 10 I, 2005, Pages 1303-1309

  Mohr, John F ^a   McKinnon, Peggy S ^b   Peymann, Patti J ^c   Kenton, Irene ^d   Septimus, Edward ^e   Okhuysen, Pablo C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c Memorial City Hospital   (United States)

^d Memorial Southeast Hospital

^e MEMORIAL HERMANN HEALTHCARE SYSTEM   (United States)

Author keywords

Ciprofloxacin; Dysglycemia; Fluoroquinolones; Gatifloxacin; Glucose homeostasis; Hyperglycemia; Hypoglycemia; Levofloxacin

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; GATIFLOXACIN; GLUCOSE; LEVOFLOXACIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; BODY WEIGHT; COMMUNITY HOSPITAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; REVIEW; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BLOOD GLUCOSE; CEFTRIAXONE; CIPROFLOXACIN; FEMALE; FLUOROQUINOLONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; MIDDLE AGED; OFLOXACIN; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES;

EID: 26044472341     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10.1303     Document Type: Review

References (41)

1. Bayer Corporation. Cipro (ciprofloxacin) package insert. West Haven, CT; 2003.
2. Bristol-Myers Squibb. Tequin (gatifloxacin) package insert. Princeton, NJ; 2003.
3. Ortho-McNeil Pharmaceuticals. Levaquin (levofloxacin) package insert. Raritan, NJ; 2003.
4. Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am 2004;88:1063-84, xii.
5. Cely CM, Arora P, Quartin AA, Kett DH, Schein RM. Relationship of baseline glucose homeostasis to hyperglycemia during medical critical illness. Chest 2004;126:879-87.
6. Fischer KF, Lees JA, Newman JH. Hypoglycemia in hospitalized patients: causes and outcomes. N Engl J Med 1986;315:1245-50.
7. Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003;163;1825-9.
8. Shilo S, Berezovsky S, Friedlander Y, Sonnenblick M. Hypoglycemia in hospitalized nondiabetic older patients. J Am Geriatr Soc 1998;46:978-82.
9. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996;117:372-6.
10. Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004;497:111-17.
11. Zunkler BJ, Wos M. Effects of lomefloxacin and norfloxacin on pancreatic B-cell ATP-sensitive K+ channels. Life Sci 2003;73:429-35.
12. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003;52:435-40.
13. Bayer Pharmaceuticals. Avelox (moxifloxacin) package insert. West Haven, CT; 2003.
14. Pfizer. Zithromax (azithromycin) package insert. New York, NY; 2002.
15. Wyeth Laboratories. Zosyn (piperacillin-tazobactam) package insert. Philadelphia, PA; 2003.
16. Pfizer. Norvasc (amlodipine) package insert. New York, NY; 2001.
17. AstraZeneca Pharmaceuticals. Zestril (lisinopril) package insert. Wilmington, DE; 2002.
18. McNeil Consumer & Specialty Pharmaceuticals. Motrin (ibuprofen) package insert. Fort Washington, PA; 1994.
19. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy 1993;13:461-4.
20. Akpunonu B, Michaelis J, Uy CN, et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2004;38:S5-15.
21. Bristol-Myers Squibb. Data on file. Princeton, NJ; 2004.
22. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004;42:295-7.
23. Roberge RJ, Kaplan R, Frank R, Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36:160-3.
24. Whiteley MS, Worlding J, Patel S, Gibbs KB. Hypoglycemia in a diabetic patient, associated with ciprofloxacin therapy. Pract Diabetes 1999;10:35.
25. Bhatia V, Bhatia R, Dhindsa S. Gatifloxacin-induced hyperglycemia. Endocr Pract 2004;10:86.
26. Arce FC, Bhasin RS, Pasmantier R. Severe hyperglycemia during gatifloxacin therapy in patients without diabetes. Endocr Pract 2004;10:40-4.
27. Donaldson AR, Vandiver JR, Finch CK. Possible gatifloxacin-induced hyperglycemia. Ann Pharmacother 2004;38:602-5.
28. LeBlanc M, Belanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy 2004;24:926-31.
29. Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC. Gatifloxacin-induced hyperglycemia. Ann Intern Med 2004;141:968-9.
30. Khovidhunkit W, Sunthornyothin S. Hypoglycemia, hyperglycemia, and gatifloxacin. Ann Intern Med 2004; 141:969.
31. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002;113:232-4.
32. Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 2002;36:1722-6.
33. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004;24:1807-12.
34. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in inflammatory research, vol 6. New York: Raven Press, 1984:1-6.
35. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004;24:743-9.
36. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000;20(6 suppl 2):49S-58.
37. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000;20(6 suppl 2):76S-86.
38. Letourneau G, Morrison H, McMorran M. Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Can Adverse React Newsletter 2003;13:1-2.
39. Frothingham R. Gatifloxacin associated with a 56-fold higher rate of glucose homeostasis abnormalities than comparator quinolones in the FDA spontaneous reporting database. Presented at the 44th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, October 30-November 2, 2004.
40. Lomaestro BM, Lodise TP. Comparison of glucose intolerance between gatifloxacin and piperacillin-tazobactam in elderly, hospitalized patients. Presented at the 44th interscience conference on antimicrobial agents and chemotherapy, Washington, DC, October 30-November 2, 2004.
41. Coblio NA, Mowrey K, McCright P, Means H, McCormick MT. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health-Syst Pharm 2004;61:2545-8.